IL-1, quo vadis?

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 324-325

  Grebe, Alena ^a   Latz, Eicke ^a,b,c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME PRECURSOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CYTOKINE RELEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MALE; RECEPTORS, INTERLEUKIN-1 TYPE I;

EID: 84861341175     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.010     Document Type: Note

References (11)

1. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 17. 10.1093/cvr/cvn120.
2. Nicklin M.J., Hughes D.E., Barton J.L., Ure J.M., Duff G.W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000, 191:303-312.
3. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
4. Keller M., Ruegg A., Werner S., Beer H. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-831.
5. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 2010, 22:28-33.
6. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357.
7. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis *. Annu Rev Immunol 2009, 27:165-197.
8. Shemesha S., Kamaria Y., Shaisha A., et al. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Atherosclerosis 2012, 222:329-336.
9. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
10. Alexander M.A., Moehle C.W., Johnson J.L., et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012, 122:70-79.
11. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.